申联生物
(688098)
| 流通市值：33.71亿 | | | 总市值：33.71亿 |
| 流通股本：4.11亿 | | | 总股本：4.11亿 |
| 利润表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 营业总收入 | 62,598,409.64 | 288,266,467.14 | 237,694,760.86 | 121,725,138.28 |
| 营业总成本 | 60,149,695.32 | 306,578,474.55 | 235,297,261.25 | 138,536,976.11 |
| 其他经营收益 | | | | |
| 营业利润 | -2,820,669.94 | -27,857,850.63 | -2,611,073.2 | -16,380,912.97 |
| 利润总额 | -2,826,900.34 | -26,310,492.99 | -1,348,620.01 | -16,264,533.38 |
| 净利润 | -2,362,468.25 | -24,971,591.4 | -3,022,872 | -15,042,391.78 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | -2,362,468.25 | -24,971,591.4 | -3,022,872 | -15,042,391.78 |
| 资产负债表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 流动资产: | | | | |
| 流动资产合计 | 495,151,244.15 | 535,901,827.05 | 547,479,057.35 | 514,502,365.24 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,034,790,052.42 | 1,006,479,209.55 | 1,012,857,824.22 | 1,022,171,620.34 |
| 资产总计 | 1,529,941,296.57 | 1,542,381,036.6 | 1,560,336,881.57 | 1,536,673,985.58 |
| 流动负债: | | | | |
| 流动负债合计 | 123,845,448.36 | 133,328,214.2 | 128,125,771.64 | 115,942,136.2 |
| 非流动负债: | | | | |
| 非流动负债合计 | 9,487,334.49 | 10,081,840.43 | 11,291,408.56 | 11,831,667.79 |
| 负债合计 | 133,332,782.85 | 143,410,054.63 | 139,417,180.2 | 127,773,803.99 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,387,389,366.2 | 1,389,120,321.1 | 1,409,893,375.64 | 1,396,745,623.14 |
| 股东权益合计 | 1,396,608,513.72 | 1,398,970,981.97 | 1,420,919,701.37 | 1,408,900,181.59 |
| 负债和股东权益合计 | 1,529,941,296.57 | 1,542,381,036.6 | 1,560,336,881.57 | 1,536,673,985.58 |
| 现金流量表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 45,113,657.09 | 278,942,649.79 | 159,813,427.48 | 85,348,055.54 |
| 经营活动现金流出小计 | 85,188,463.64 | 245,865,808.25 | 177,919,521.6 | 124,737,109.02 |
| 经营活动产生的现金流量净额 | -40,074,806.55 | 33,076,841.54 | -18,106,094.12 | -39,389,053.48 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 177,832,937.46 | 594,069,514.73 | 477,431,545.51 | 352,686,898.91 |
| 投资活动现金流出小计 | 177,516,789.54 | 643,233,904.97 | 493,779,805.21 | 369,158,558.85 |
| 投资活动产生的现金流量净额 | 316,147.92 | -49,164,390.24 | -16,348,259.7 | -16,471,659.94 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | 16,317.38 | 16,317.38 | 16,317.38 |
| 筹资活动现金流出小计 | 161,203 | 3,522,577.06 | 2,770,862.95 | 2,711,877.58 |
| 筹资活动产生的现金流量净额 | -161,203 | -3,506,259.68 | -2,754,545.57 | -2,695,560.2 |
| 汇率变动对现金及现金等价物的影响 | -23.13 | -33.72 | -17.51 | -6.29 |
| 现金及现金等价物净增加额 | -39,919,884.76 | -19,593,842.1 | -37,208,916.9 | -58,556,279.91 |
| 期末现金及现金等价物余额 | 51,655,366.94 | 91,575,251.7 | 73,960,176.9 | 52,612,813.89 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -19,593,842.1 | - | -58,556,279.91 |